Chondroitin sulfate in osteoarthritis treatment in patients with comorbid cardiovascular diseases: hypertension, atherosclerosis, coronary heart disease
Osteoarthritis (OA) is the most common joint disease globally, and its incidence increases with age – up to 80–90% in people over 60 years. There is a high comorbidity between OA and cardiovascular diseases (CVD), such as arterial hypertension (AH), atherosclerosis, and coronary heart disease (CHD)....
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2021-06-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/1586 |
| _version_ | 1827062793849798656 |
|---|---|
| author | O. A. Shavlovskaya I. A. Bokova I. V. Sarvilina N. I. Shavlovskiy Yu. D. Yukhnovskaya |
| author_facet | O. A. Shavlovskaya I. A. Bokova I. V. Sarvilina N. I. Shavlovskiy Yu. D. Yukhnovskaya |
| author_sort | O. A. Shavlovskaya |
| collection | DOAJ |
| description | Osteoarthritis (OA) is the most common joint disease globally, and its incidence increases with age – up to 80–90% in people over 60 years. There is a high comorbidity between OA and cardiovascular diseases (CVD), such as arterial hypertension (AH), atherosclerosis, and coronary heart disease (CHD). The main objectives of OA therapy include pain reduction, cartilage matrix preservation, safe profile in patients with comorbid diseases, minimal adverse effects. In addition, the drug should be comparable in analgesic effects with nonsteroidal anti-inflammatory drugs (NSAIDs). Such drugs include structural-modifying agents – symptomatic slow-acting drugs for osteoarthritis (SYSADOA), one of which is chondroitin sulfate (CS). According to the 2019–2020 International and Russian guidelines, only pharmaceutical-grade CS is recommended for use. The high efficacy of intramuscular administration of CS in patients with OA, lower back pain, and comorbid diseases (AH, CHD, atherosclerosis) has been proven. CS is prescribed for a long treatment course – up to two months. |
| first_indexed | 2024-04-10T02:01:03Z |
| format | Article |
| id | doaj.art-8e27352f66d840aca1cfe56bfce6ede6 |
| institution | Directory Open Access Journal |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| last_indexed | 2025-02-18T20:01:29Z |
| publishDate | 2021-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj.art-8e27352f66d840aca1cfe56bfce6ede62024-10-17T16:15:28ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422021-06-0113311311810.14412/2074-2711-2021-3-113-1181145Chondroitin sulfate in osteoarthritis treatment in patients with comorbid cardiovascular diseases: hypertension, atherosclerosis, coronary heart diseaseO. A. Shavlovskaya0I. A. Bokova1I. V. Sarvilina2N. I. Shavlovskiy3Yu. D. Yukhnovskaya4International University of Restorative MedicineI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaMedical Centre «Novomeditsina»I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaOsteoarthritis (OA) is the most common joint disease globally, and its incidence increases with age – up to 80–90% in people over 60 years. There is a high comorbidity between OA and cardiovascular diseases (CVD), such as arterial hypertension (AH), atherosclerosis, and coronary heart disease (CHD). The main objectives of OA therapy include pain reduction, cartilage matrix preservation, safe profile in patients with comorbid diseases, minimal adverse effects. In addition, the drug should be comparable in analgesic effects with nonsteroidal anti-inflammatory drugs (NSAIDs). Such drugs include structural-modifying agents – symptomatic slow-acting drugs for osteoarthritis (SYSADOA), one of which is chondroitin sulfate (CS). According to the 2019–2020 International and Russian guidelines, only pharmaceutical-grade CS is recommended for use. The high efficacy of intramuscular administration of CS in patients with OA, lower back pain, and comorbid diseases (AH, CHD, atherosclerosis) has been proven. CS is prescribed for a long treatment course – up to two months.https://nnp.ima-press.net/nnp/article/view/1586osteoarthritislow back painstructural modifying agentschondroitin sulfateatherosclerosishypertensioncoronary heart disease |
| spellingShingle | O. A. Shavlovskaya I. A. Bokova I. V. Sarvilina N. I. Shavlovskiy Yu. D. Yukhnovskaya Chondroitin sulfate in osteoarthritis treatment in patients with comorbid cardiovascular diseases: hypertension, atherosclerosis, coronary heart disease Неврология, нейропсихиатрия, психосоматика osteoarthritis low back pain structural modifying agents chondroitin sulfate atherosclerosis hypertension coronary heart disease |
| title | Chondroitin sulfate in osteoarthritis treatment in patients with comorbid cardiovascular diseases: hypertension, atherosclerosis, coronary heart disease |
| title_full | Chondroitin sulfate in osteoarthritis treatment in patients with comorbid cardiovascular diseases: hypertension, atherosclerosis, coronary heart disease |
| title_fullStr | Chondroitin sulfate in osteoarthritis treatment in patients with comorbid cardiovascular diseases: hypertension, atherosclerosis, coronary heart disease |
| title_full_unstemmed | Chondroitin sulfate in osteoarthritis treatment in patients with comorbid cardiovascular diseases: hypertension, atherosclerosis, coronary heart disease |
| title_short | Chondroitin sulfate in osteoarthritis treatment in patients with comorbid cardiovascular diseases: hypertension, atherosclerosis, coronary heart disease |
| title_sort | chondroitin sulfate in osteoarthritis treatment in patients with comorbid cardiovascular diseases hypertension atherosclerosis coronary heart disease |
| topic | osteoarthritis low back pain structural modifying agents chondroitin sulfate atherosclerosis hypertension coronary heart disease |
| url | https://nnp.ima-press.net/nnp/article/view/1586 |
| work_keys_str_mv | AT oashavlovskaya chondroitinsulfateinosteoarthritistreatmentinpatientswithcomorbidcardiovasculardiseaseshypertensionatherosclerosiscoronaryheartdisease AT iabokova chondroitinsulfateinosteoarthritistreatmentinpatientswithcomorbidcardiovasculardiseaseshypertensionatherosclerosiscoronaryheartdisease AT ivsarvilina chondroitinsulfateinosteoarthritistreatmentinpatientswithcomorbidcardiovasculardiseaseshypertensionatherosclerosiscoronaryheartdisease AT nishavlovskiy chondroitinsulfateinosteoarthritistreatmentinpatientswithcomorbidcardiovasculardiseaseshypertensionatherosclerosiscoronaryheartdisease AT yudyukhnovskaya chondroitinsulfateinosteoarthritistreatmentinpatientswithcomorbidcardiovasculardiseaseshypertensionatherosclerosiscoronaryheartdisease |